Business Update / Product Approval Support
OneSource Specialty Pharma Supports Second Generic Semaglutide Approval in Canada
NSE
onesource
BSE
544292
OneSource Specialty Pharma has supported its partner in securing Health Canada approval for a generic semaglutide (Ozempic equivalent), marking the second generic approval in Canada and strengthening its global CDMO positioning
PRICE-SENSITIVE TRIGGER
Event: Regulatory Approval (Partner-led) – Generic Semaglutide
Type: Business Update / Product Approval Support
Impact: Positive
Immediate Effect: Enhances credibility in complex injectable ,manufacturing and boosts global CDMO positioning
What Happened ?
OneSource Specialty Pharma Limited announced that:
- Its partner Orbicular, along with a Canadian partner
- Has received Health Canada approval for:
- Generic version of Ozempic (semaglutide injection)
This marks:
- Second generic semaglutide approval in Canada
- Positions partners as early entrants in a high-value market
key highlights
Product & Market Significance:
- Product: Generic Semaglutide (Ozempic equivalent)
- Market:
- One of the largest and fastest-growing diabetes/obesity drug markets
- Canada = world’s second-largest semaglutide market
OneSource Role:
- Acted as manufacturing partner (CDMO)
- Provided:
- End-to-end manufacturing capabilities
- Commercial supply:
- From US FDA-approved Bengaluru facility
Strategic Impact:
- Strengthens presence in:
- Complex peptide-based injectables
- Reinforces:
- Global CDMO capabilities
- Compliance and regulatory strength
- Follows:
- Recent US tentative approval milestone
Business Momentum:
- Builds on recent product launches in India
- Expands global partner ecosystem
- Enhances positioning in:
- Biologics
- Drug-device combinations
Note:
Revenue impact not quantified yet; depends on commercialization scale
Risk Analysis
Key Risks
- Dependency on partner commercialization
- Pricing pressure in generic markets
- Regulatory compliance in multiple jurisdictions
- Scale-up and supply chain execution
Worst Case Scenario
- Delays in commercialization or pricing erosion could limit expected revenue upside
Risk Level: Medium
Company Commentary
- Highlighted:
- Back-to-back global approvals
- Strength of CDMO platform
- Emphasized:
- Technical expertise
- Compliance standards
- Ability to scale complex programs
- Reinforced:
- Role in enabling global commercialization
Official Exchange Filing: OneSource Specialty Pharma Limited